Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis

Article ID	Journal	Published Year	Pages	File Type
6091561	Clinical Gastroenterology and Hepatology	2014	14 Pages	PDF

Abstract

In a controlled phase 2B trial, vaniprevir with peginterferon and ribavirin significantly increased rates of SVR among treatment-experienced patients with chronic HCV genotype 1 infection, compared with re-treatment with peginterferon and ribavirin alone. Vaniprevir generally was well tolerated for up to 48 weeks in patients with compensated cirrhosis. ClinicalTrials.gov number, NCT00704405.

Keywords

SVR LLQ RAV P/R peginterferon alfa and ribavirin RVR mITT modified intention-to-treat Resistance-associated variants lower limit of quantification direct-acting antiviral agent Fibrosis Hepatitis C virus HCV rapid virologic response Sustained virologic response Clinical trial

Related Topics

Health Sciences Medicine and Dentistry Gastroenterology

Preview

Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis

Authors

Maribel Rodriguez-Torres, Albrecht Stoehr, Edward J. Gane, Lawrence Serfaty, Eric Lawitz, Amy Zhou, Michael Bourque, Sanhita Bhanja, Julie Strizki, Richard J.O. Barnard, Peggy M.T. Hwang, Mark J. DiNubile, Niloufar Mobashery,